In 2017, the number of pending patent applications awaiting a
final decision was reduced by 7.6%. The backlog reduction was the
result of a combination of factors, including a 25% increase in the
Brazilian Patent and Trademark Office's (INPI) staff,
optimisation of internal procedures, and improvements in the
INPI's electronic systems in particular. These proposed
measures were promising, but 2017 still closed with worrying
backlog statistics.
The overall average consists of 10.23 years from filing until
grant, but the decision time for applications in the pharma field
reaches a disappointing average of 13.63 years, behind only
telecoms applications. The backlog was significantly worse in the
past for pharmaceutical cases, due to the double patentability
examination carried out by the INPI and the Brazilian National
Health Surveillance Agency (ANVISA).